Aspire Biopharma Holdings, Inc. ASBP
is an early-stage biopharmaceutical company. As a Delaware corporation formed in February 2025, the Company engages in the business of
developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business
Combination we were a privately held Puerto Rico corporation incorporated in September 2021. Our internet address is www.aspirebiolabs.com.
expect to generate revenue through developing and marketing drugs and nutraceuticals using the technology for the novel sublingual delivery.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.2K | — | — | — | — | — |
| Cost of revenue | $6.3K | — | — | — | — | — |
| Gross profit | -$116 | — | — | — | — | — |
| R&D | $923.9K | $144.4K | — | — | — | — |
| SG&A | $17.6M | $940.4K | $1.3M | $976.3K | — | — |
| Total operating expenses | $19.4M | $1.2M | $1.3M | $976.3K | — | — |
| Operating income | -$19.4M | -$1.2M | — | — | — | — |
| Interest expense | $8.5M | $98.0K | — | — | — | — |
| Pre-tax income | -$24.5M | -$1.3M | — | — | — | — |
| Income tax | — | $1.0K | — | — | — | — |
| Net income | -$24.5M | -$1.3M | $4.5M | $3.3M | — | — |
| EPS, diluted | -16.38 | -1.90 | — | — | — | — |
| Shares, diluted (wtd. avg.) | 1.5M | 689,913 | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.0M | $3.6K | $11.2K | $497.3K | — | — |
| Inventory | $253.2K | — | — | — | — | — |
| Total current assets | $1.3M | $148.0K | $81.2K | $1.1M | $293.2K | — |
| Total assets | $1.3M | $148.0K | $20.0M | $300.2M | $293.2K | — |
| Accounts payable | $1.0M | $310.2K | $152.0K | $180.6K | $273 | — |
| Total current liabilities | $7.6M | $1.7M | $403.3K | $303.3K | $293.7K | — |
| Total liabilities | $7.7M | $1.7M | $403.3K | $11.1M | $293.7K | — |
| Retained earnings | -$27.3M | -$2.8M | -$11.3M | -$9.9M | -$25.5K | — |
| Total equity | -$6.4M | -$1.5M | -$487.9K | -$9.9M | -$475 | $0 |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.9M | -$265.2K | -$653.1K | -$1.4M | — | — |
| Stock-based compensation | $14.1M | — | — | — | — | — |
| Investing cash flow | — | $13.8M | $284.9M | -$294.7M | — | — |
| Financing cash flow | $5.9M | $257.6K | -$284.8M | $296.6M | — | — |
| Buybacks | — | $13.8M | $284.9M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-016123.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $6.2K |
| Gross profit | — | — | — | — | — | -$116 |
| Net income | — | — | $3.3M | $4.5M | -$1.3M | -$24.5M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |